A Novel Canine Mammary Cancer Cell Line: Preliminary Identification and Utilization for Drug Screening Studies

Area of Science:

• Veterinary Oncology
• Cancer Cell Line Development
• Comparative Pathology

Background:

• Canine malignant mammary tumors are aggressive and have a poor prognosis.
• There is a need for reliable cell models to study canine mammary cancer and test potential therapies.

Purpose of the Study:

• To establish and characterize a novel canine mammary cancer cell line (B-CMT).
• To utilize B-CMT as an in vitro model for screening therapeutic drugs against canine mammary tumors.

Main Methods:

• Establishment and long-term culture of the B-CMT cell line.
• Characterization using qRT-PCR, immunofluorescence, western blot, and immunohistochemistry.
• In vivo studies in mice to confirm tumor formation from B-CMT cells.
• In vitro drug cytotoxicity assays.

Main Results:

• B-CMT cells exhibited rapid proliferation with a population doubling time of 33.6 hours.
• The cell line lacked expression of HER-2, ER, and PR, but showed decreased CDH1 and increased GATA3.
• Positive expression of hypoxia-inducible factor-1α (HIF-1α) was observed.
• Rapamycin and imatinib demonstrated significant in vitro cytotoxicity and induced cell cycle arrest.

Conclusions:

• The B-CMT cell line is a viable model for canine mammary cancer research.
• This cell line can be used for in vitro drug screening and studying tumor microenvironment and drug resistance.